RobertoACalleMDFACE, FACP
Endocrinology • Tarrytown, NYDiabetes, Lipid Metabolism, Obesity
Executive Medical Director
Dr. Calle is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Regeneron Pharmaceuticals
777 Old Sawmill River Road
Tarrytown, NY 10591- Is this information wrong?
Education & Training
Yale-New Haven Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1987 - 1989
University of Michigan Health SystemResidency, Internal Medicine, 1984 - 1987
University of Puerto Rico School of MedicineClass of 1984, MD
Awards, Honors, & Recognition
- Alpha Omega Alpha Honor Medical Society 1983
Publications & Presentations
PubMed
- 8 citationsThe prevalence of low muscle mass associated with obesity in the USA.Dana J Murdock, Ning Wu, Joseph S Grimsby, Roberto A Calle, Stephen Donahue, David J Glass, Mark W Sleeman, Robert J Sanchez> ;Skeletal Muscle. 2022 Dec 21
- 28 citationsNon-Invasive Biomarkers of Nonalcoholic Steatohepatitis: the FNIH NIMBLE project.Arun J Sanyal, Sudha S Shankar, Roberto A Calle, Anthony E Samir, Claude B Sirlin, Sarah P Sherlock, Rohit Loomba, Kathryn J Fowler, Clayton A Dehn, Helen Heymann, Tan...> ;Nature Medicine. 2022 Mar 1
- 85 citationsACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a...Roberto A. Calle, Neeta B. Amin, Santos Carvajal-Gonzalez, Trenton T. Ross, Arthur Bergman, Sudeepta Aggarwal, Collin Crowley, Anthony Rinaldi, Jessica Mancuso, Naresh...> ;Nature Medicine. 2021 Oct 1
- Join now to see all
Journal Articles
- A First-In-Patient (Phase Ib) Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and CachexiaJ. Crawford, R.A. Calle, S.M. Collins, Y. Weng, Shannon L. Lubaczewski, C. Buckridge, E. Q Wang, M.A. Harrington, A. Tarachandani, M.I. Rossulek, J.H Revkin., Clinical Cancer Research, 2023
- Diagnostic performance of circulating biomarkers for non-alcoholic steatohepatitisA. J. Sanyal, S.S. Shankar, K.P. Yates, J. Bolognese, E. Daly, C. A. Dehn, B. Neuschwander-Tetri, K. Kowdley, R. Vuppalanchi, C. Behling, J. Tonascia, A. Samir, C. Sir..., Nature Medicine, 2023
- Repeatability of MRI biomarkers in non-alcoholic fatty liver disease: the NIMBLE ConsortiumK. Fowler, S. Venkatesh, N. Obuchowski, M. Middleton, J. Chen, K. Pepin, J. Magnuson, K. Brown, D. Batakis, W. Henderson, S. Shankar, T. Kamphaus, A. Pasek, R. Calle, ..., Radiology, 2023
- Join now to see all
Committees
- Co-Chair, Non-Invasive Biomarkers of Metabolic Liver Disease - NIMBLE FNIH Project 2018 - Present
- Member, American Diabetes Association New England - Community Leaders Board 2017 - Present
- Co-Chair, FNIH Biomarkers Consortium - Metabolic Disorders Steering Committee 2014 - Present
- Member, FNIH Biomarkers Consortium - Metabolic Disorders Steering Committee 2009 - 2013
Professional Memberships
- Fellow
- Member
- Member
- Fellow
- Member
Other Languages
- French, Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
